Reference number : 236-2018-2019-Q2-00141, amendment number : , agreement type : G, recipient legal name : Mansouri, Alireza, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5G 2C4, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 220000.0, agreement start date : 2018-07-01, agreement end date : 2022-06-30, description english : A multi-phase clinical trial to establish biological proof-of-concept, determine safety and maximum tolerated dose, and assess efficacy of neoadjuvant ketoconazole and posaconazole in patients with recurrent high grade gliomas, description french : A multi-phase clinical trial to establish biological proof-of-concept, determine safety and maximum tolerated dose, and assess efficacy of neoadjuvant ketoconazole and posaconazole in patients with recurrent high grade gliomas, expected results english : nan, expected results french : nan, additional information english : nan, additional information french : nan, owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada